Program
SMUP-IA-01(low-dose)
Also written as “SMUP-IA-01(mid-dose)”, “SMUP-IA-01(high-dose)” and “SMUP-IA-01(low dose)”.
Its studies are mostly in Osteoarthritis, Knee, led by Medipost.
Furthest: phase 2, since Dec 12, 20214 company-led studies, 2 open or runningNext primary completion: Mar 20, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Medipost | 42 open or running | phase 2since Dec 12, 2021 | Jul 17, 2019 | Mar 20, 2027phase 2 · NCT06798727 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 17, 2019First study: phase 1 study in Osteoarthritis, KneeFirst studyNCT04037345 · 12 enrolled · Korea, Republic of
- Apr 6, 2020Phase 1 study in Osteoarthritis, KneeNCT04339504 · 12 planned · Korea, Republic of
- Dec 12, 2021Phase 2 study in Osteoarthritis, KneeNCT05182034 · 94 enrolled · Korea, Republic of
- Jan 23, 2025Phase 2 study in Osteoarthritis, KneeNCT06798727 · 84 enrolled · Korea, Republic of
Ahead
- Mar 20, 2027Primary completion: phase 2 study in Osteoarthritis, KneeNCT06798727
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06798727Osteoarthritis, Knee · Korea, Republic of | 2 | Active, not recruiting | Mar 20, 2027 | 84 |
| NCT05182034Osteoarthritis, Knee · Korea, Republic of | 2 | Completed | Oct 17, 2023 | 94 |
| NCT04339504Osteoarthritis, Knee · Korea, Republic of | 1 | Recruiting | Dec 2025 | 12 |
| NCT04037345Osteoarthritis, Knee · Korea, Republic of | 1 | Completed | Nov 12, 2020 | 12 |
How it is read
Names in the registry
- “SMUP-IA-01(low-dose)”, 3 entries
- “SMUP-IA-01(mid-dose)”, 3 entries
- “SMUP-IA-01(high-dose)”, 2 entries
- “SMUP-IA-01(low dose)”, 1 entry
- “SMUP-IA-01(mid dose)”, 1 entry
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.